# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pablo Neruda (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML051-SYN
- Date: 2026-06-01
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marisol Fairweather-Diaz, MD
- Calendar frame: modern shifted

## Reason for visit

New patient with four months of urinary symptoms and six weeks of right hip and low back pain: examination, PSA and baseline tests, pain control, the staging and biopsy plan, and medical oncology referral. **S**

## Historical basis

- Pablo Neruda was born on 12 July 1904 in the town of Parral in Chile. His father was a railway employee, and his mother, a teacher, died shortly after his birth; he spent his childhood and youth in Temuco. **D**
- He used the pen name Pablo Neruda from 1920. The Nobel Prize biography gives his real name as Neftalí Ricardo Reyes Basoalto; the Library of the National Congress of Chile gives his birth name as Ricardo Eliecer Neftalí Reyes Basoalto and records that a court judgment of 28 December 1946 changed it to Pablo Neruda. **D**
- Between 1927 and 1935 he held a series of honorary consulships in Burma, Ceylon, Java, Singapore, Buenos Aires, Barcelona and Madrid; in 1945 he was elected a senator of the Republic and joined the Communist Party of Chile. **D**
- After the 1970 presidential election he was named Chile's ambassador to France; the Senate approved the appointment on 21 January 1971 and he presented his credentials at the end of that month. He resigned the post in 1972 and returned to Chile in November 1972. **D**

9 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- He wants to know what the pain and the urinary symptoms mean, and to be told plainly. **S**
- He wants to keep writing every morning and to carry on his duties as ambassador. **S**
- He wants important discussions held in Spanish. **S**

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Medications and allergies

- Amlodipine 5 mg oral tablet, one tablet daily **S**
- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- No historical medical events recorded.

## Procedures and immunizations

- No procedures before this visit. **S**
- 2020-09-21: Tdap vaccine **S**
- 2025-10-14: High-dose influenza vaccine, last season **S**

## Family history

- mother: Died shortly after his birth; cause not recorded in the cited source **D** (CLM-0001)

## Measurements

PSA: 46.8 ng/mL (high); Total testosterone: 468 ng/dL; Hemoglobin: 13.6 g/dL; White cell count: 6.4 10*3/uL; Platelets: 248 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.3 mmol/L; Glucose: 104 mg/dL (high); Creatinine: 0.96 mg/dL; eGFR (CKD-EPI 2021): 87 mL/min/1.73 m²; Calcium: 9.6 mg/dL; ALT: 22 U/L; AST: 24 U/L; Alkaline phosphatase: 168 U/L (high); Albumin: 4.1 g/dL; LDH: 208 U/L; Hemoglobin A1c: 5.9% (high); Total cholesterol: 214 mg/dL (high); HDL cholesterol: 46 mg/dL; LDL cholesterol: 140 mg/dL (high); Triglycerides: 140 mg/dL; 25-hydroxyvitamin D: 22 ng/mL (low); PHQ-9: 6; IPSS total (0 to 35): 17; Pain, 0 to 10: 6. All results are synthetic.

BP 146/88 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 92.4 kg; BMI 29.2 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, articulate and warm; worried about what the pain means; sleep broken by pain and nocturia; PHQ-9 score 6. Functional status: Independent in all daily activities; walking limited to about 20 minutes by right hip pain; ECOG performance status 1. Physical examination is intentionally limited. **S**

## Assessment

1. Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmed; status draft. **S**
2. Essential hypertension for five years, on amlodipine; status draft. **S**
3. Prediabetes (hemoglobin A1c 5.9%); status draft. **S**

## Plan

- Medical oncology (genitourinary) consultation within two weeks for suspected metastatic prostate cancer: diagnosis, staging, systemic treatment, radiotherapy, bone health and genetic testing. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026) **S**
- Diagnosis and staging: multiparametric MRI of the prostate, an MRI-targeted transperineal biopsy at the urology practice, CT of the chest, abdomen and pelvis, a bone scan, and PSMA PET/CT. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026); CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026) **S**
- Bone pain: acetaminophen 1000 mg up to three times a day; spinal cord compression warning signs explained in Spanish, with same-day assessment for new leg weakness or numbness, or loss of bladder or bowel control. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026) **S**
- Care in Spanish, his first language: a professional medical interpreter for every major discussion, written plans in Spanish, appointments placed around his morning writing and his official duties. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026) **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026), National Comprehensive Cancer Network
- Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026), American Urological Association and Society of Urologic Oncology
- Lowrance W, et al. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). J Urol 2023;209(6):1082-1090 (2023), American Urological Association and Society of Urologic Oncology
- Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014), American Cancer Society
- CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026), Aether Forge
